G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

Yield10 Bioscience

Biotech stocks are a tricky bunch, prone to wild moves and technical patterns that are tough to nail down.

2 Biotech Stocks to Watch Under $20

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q1 2024 Earnings Conference Call May 1, 2024 8:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry - Chief Commercial Officer Raj Malik - Chief Medical Officer John Umstead - Chief Financial Officer Conference Call Participants Gil Blum - Needham Joseph Thome - TD Cowen Laura Prendergast - Raymond James David Nierengarten - Wedbush Steve Bersey - H.C. Wainwright Operator Good day, and thank you for standing by.

G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.53 per share a year ago.

G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates

- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) Will Be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in 1L Metastatic Triple Negative Breast Cancer (mTNBC) Is Expected to Occur in Late Second Quarter of 2024 - - Cash Runway Expected to Extend into the Third Quarter of 2025 - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2024.

G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C. and BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, and Pepper Bio, the world's first transomics drug discovery and development company, announced a global licensing agreement (excluding the Asia-Pacific region) for lerociclib for all indications except for certain radioprotectant uses.

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib

RESEARCH TRIANGLE PARK, N.C., April 17, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter of 2024 on Wednesday May 1, 2024, at 8:30 a.m.

G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024

RESEARCH TRIANGLE PARK, N.C., April 04, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 8:45 AM ET.

G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

G1 Therapeutics is a biopharmaceutical company that develops and commercializes advanced oncology treatments. Its flagship product, Cosela, is an FDA-approved drug for reducing chemotherapy side effects in patients with Extensive-Stage Small Cell Lung Cancer. The company's research pipeline includes exploring new indications for Trilaciclib in breast and bladder cancer, reporting a 29% increase in Cosela's net revenues in Q4 2023.

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript

G1 Therapeutics (GTHX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.73 per share a year ago.

G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates

- Achieved $46.3 Million in Net Revenue from Sales of COSELA® (trilaciclib) for Full Year 2023, Representing 48% Growth Over 2022; Provided 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Net COSELA Revenue Grew 29% in the Fourth Quarter of 2023 to $13.9 Million - - Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in Metastatic Triple Negative Breast Cancer is Estimated to Occur in the Third Quarter of 2024 - - Presented New Analyses Indicating that Patients Who Previously Received Trilaciclib in a Clinical Trial Setting Experienced Improved Overall Survival with Subsequent Anticancer Therapies - - Provided Initial Results from Phase 2 Trial in Combination with a TROP2 Antibody-Drug Conjugate Indicating Improvements in Overall Survival for Patients Receiving Trilaciclib - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the fourth quarter and full year ended December 31, 2023.

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will participate in a Breast & Lung Cancer Corporate Panel Discussion during the TD Cowen 44th Annual Health Care Conference on Wednesday March 6, 2024 at 9:10 AM EST.

G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the fourth quarter and full year 2023 on Wednesday February 28, 2024, at 8:30 a.m.

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

G1 Therapeutics (NASDAQ: GTHX ) stock is falling hard on Tuesday after the biopharmaceutical company provided an interim update on a Phase 3 clinical trial of trilaciclib as a breast cancer treatment. This clinical trial has trilaciclib being used in combination with gemcitabine and carboplatin as a first line treatment for metastatic triple negative breast cancer (mTNBC).

Why Is G1 Therapeutics (GTHX) Stock Down 45% Today?

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent DMC

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

G1 Therapeutics has provided pipeline updates, including encouraging preliminary overall survival data from a phase 2 study of trilaciclib in combination with sacituzumab govitecan for advanced triple-negative breast cancer. The company aims to pursue global partnerships for the release and support of trilaciclib if positive results are obtained from the ongoing trials. G1 Therapeutics' cash runway has been extended into early 2025, providing more time to address FDA filings and potential partnerships.

G1 Therapeutics: New Financials And Big Data Readout Alert

- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate (ADC) Sacituzumab Govitecan (SG) Suggest a Potentially Meaningful Improvement in Overall Survival (OS) for Patients Receiving Trilaciclib - - COSELA® (trilaciclib) Vial Volume Growth Accelerated in the Fourth Quarter of 2023 with 19% Growth Over Prior Quarter - - Interim OS Analysis of Pivotal 1L Triple Negative Breast Cancer (TNBC) for Trilaciclib is Expected in the First Quarter of 2024 - - Cash Runway Expected into 2025 - RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced new clinical, commercial and corporate updates, including encouraging preliminary overall survival (OS) data from the Company's ongoing Phase 2 trial of trilaciclib in combination with the ADC sacituzumab govitecan (SG) in patients with TNBC.

G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey will provide a corporate presentation during the 42nd Annual J.P.

G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

G1 Therapeutics' lead drug trilaciclib experienced setbacks, but recent presentations on its potential benefits in breast cancer have sparked interest in the stock. Trilaciclib is designed to protect normal cells during chemotherapy and has been approved for small cell lung cancer. The company's financials show a cash runway that may not be sufficient, but positive data readouts in Q1 2024 could lead to a major recovery.

G1 Therapeutics: Flying Low, Too Low

Aclaris Therapeutics

Checkpoint Therapeutics

2Seventy Bio

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.

Best Penny Stocks To Buy? 4 To Watch With Big News This Week

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent

G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that an abstract exploring the long-term impact of trilaciclib on survival outcomes in patients with metastatic triple negative breast cancer (mTNBC) from the Company's Phase 2 trial (NCT02978716) will be presented in a poster session during the upcoming 2023 San Antonio Breast Cancer Symposium (SABCS), held December 5th through 9th in San Antonio, TX.

G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium

G1 Therapeutics, Inc. (NASDAQ:GTHX ) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Will Roberts – Vice President-Communications Jack Bailey – Chief Executive Officer Andrew Perry – Chief Commercial Officer Raj Malik – Chief Medical Officer John Umstead – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Dane Leone – RJF Anupam Rama – JPMorgan Troy Langford – TD Cowen Operator Good day and thank you for standing by. Welcome to the G1 Therapeutics Third Quarter 2023 Financial Results Call.

G1 Therapeutics, Inc. (GTHX) Q3 2023 Earnings Call Transcript

- Recognized Total Revenue of $12.3 Million, Including $10.8 Million in Net COSELA® (trilaciclib) Revenue; Vial Volume Grew 3% Over Prior Quarter - - Confirmed Expectation of Interim Overall Survival (OS) Analysis for Pivotal Phase 3 PRESERVE 2 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Reiterated Expectation of Initial OS Results from Phase 2 Trial of Trilaciclib in Combination with an Antibody-Drug Conjugate (ADC) in the First Quarter of 2024 - - COSELA Recommended in Updated American Society of Clinical Oncology (ASCO) Small Cell Lung Cancer (SCLC) Guidelines - - Management to Host Webcast and Conference Call today at 8:30 AM ET - RESEARCH TRIANGLE PARK, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update for the third quarter ended September 30, 2023.

G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights

BioXcel Therapeutics

ParaZero Technologies Ltd

Sirius XM Holdings Inc

Ready to dive into the volatile world of penny stocks? You've got your work cut out for yourself if this is your first foray into the stock market.

News for G1 Therapeutics Stock (GTHX)